Global Kratom Coalition Applauds HHS Crackdown on Dangerous Synthetic Kratom Derivatives
The Global Kratom Coalition (GKC) today applauded the U.S. Department of Health and Human Services (HHS) for taking decisive action to protect public health by moving to schedule products that contain high concentrations of 7-hydroxymitragynine (7-OH or '7'). Scheduled drugs are those with a high potential for abuse, with no currently accepted medical use in treatment in the United States, and a lack of accepted safety for use under medical supervision.
The announcement, made by Health Secretary Robert F. Kennedy Jr. and U.S. Food and Drug Administration (FDA) Commissioner Dr. Marty Makary, targets manipulated, high-potency, synthetic products like '7' that are opioids masquerading as dietary supplements and are being sold online and in smoke shops across the country.
The introduction of these products in the last two years has raised alarm among public health experts and responsible kratom advocates alike, who warn that these synthetic products pose a serious risk to consumers and undermine the safe, traditional use of kratom leaf.
'The Department of Health and Human Services is showing bold, science-driven leadership by taking aim at these rogue 7-OH products,' said Walker Gallman, legislative director of the Global Kratom Coalition. 'Secretary Kennedy and Commissioner Makary deserve enormous credit for drawing a clear line between dangerous synthetics and the natural plant. This is a huge win for public health and for millions of Americans who responsibly use leaf kratom to improve their quality of life.'
HHS made clear that natural leaf kratom is not the target of this action. Federal officials have rightly distinguished between the traditionally used botanical with centuries of safe use and synthetic derivatives like '7,' which pose significant health risks due to their potency and opioid-like effects. This distinction is critical to protect public health while preserving access to natural kratom for the millions of Americans who use it safely and responsibly.
Today's announcement follows FDA actions taken earlier this month. The FDA has already begun ramping up enforcement, issuing seven warning letters to manufacturers of 7-OH products. This action sets the stage for stronger measures ahead, including potential product seizures and civil penalties.
Today's announcement also featured strong support from Sen. Markwayne Mullin (R-Okla.), who has been an advocate for distinguishing natural leaf kratom from synthetic opioids, as well as powerful testimony from natural leaf kratom consumer Melody Woolf of Kalamazoo, Michigan.
Woolf, a longtime advocate for natural kratom, described how natural kratom leaf helped her in her daily life but warned that synthetic 7-OH products represent a dangerous and misleading alternative.
'It was only the powdered kratom leaf that saved my life,' Woolf testified. 'Now I'm seeing something very dangerous happen. 7-OH is being sold over the counter, and it's not the plant. It's concentrated and addictive. People think it's kratom, but it's not. And it's dragging some back toward opioid use. 7-OH needs to be off the shelves.'
Gallman added, 'Melody's story is one of thousands. She represents what we're fighting for—access to natural, responsibly regulated kratom. We applaud HHS for standing with consumers like her and protecting them from deceptive, dangerous knockoffs.'
The Global Kratom Coalition encourages HHS to work closely with the Drug Enforcement Administration (DEA) to move swiftly through the federal scheduling process for synthetically derived 7-hydroxymitragynine products. Coordinated action is essential to ensure these dangerous, highly concentrated substances are removed from the market before they can cause further harm. By partnering on enforcement and regulation, HHS and DEA can protect consumers while preserving access to safe, natural kratom leaf.
About Global Kratom Coalition
The Global Kratom Coalition is an alliance of kratom consumers, experts, and industry leaders dedicated to protecting access to kratom while advancing scientific research, driving consumer education, and developing robust regulations to protect consumers. For more information, visit globalkratomcoalition.org.
Media Contact
Patrick George
+1 916-202-1982
[email protected]
###
SOURCE: Global Kratom Coalition
Copyright 2025 EZ Newswire
https://app.eznewswire.com/news/global-kratom-coalition-hhs-crackdown-synthetic-derivatives
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Boston Globe
21 minutes ago
- Boston Globe
A delicious irony: Why Trump prefers Mexican Cola-Cola
Get The Gavel A weekly SCOTUS explainer newsletter by columnist Kimberly Atkins Stohr. Enter Email Sign Up Why are Mexican Cokes sweetened with sugar and US Cokes sweetened with high-fructose corn syrup? Because in the United States, high-fructose corn syrup is cheaper than sugar thanks to a long history of corn subsidies and sugar tariffs. In my home state of Illinois, I live surrounded by fields growing corn not for eating but for processing — into ethanol, animal feed, and high-fructose corn syrup. Advertisement Outside this country, however, cane sugar is the default sweetener. That's why Mexican Coke tastes different — some say it's more authentically sweet. The soft drink has become a cult favorite, a symbol of nostalgia and purity in a market saturated with manufactured sweetness. It's also a reminder of how deeply our food systems are shaped by policy decisions, not just taste. Advertisement This isn't the first time Coca-Cola has been the subject of national discussion. In the early 20th century, the US government took Coca-Cola to court under the Pure Food and Drug Act of 1906 for 'misbranding' and 'adulteration.' At the time, the drink contained negligible amounts of both coca and kola (with their implied medicinal claims as stimulants) but significant amounts of caffeine. The case went all the way to the Fast forward to today and we're in a very different moment. The Trump administration is working to gut and undermine many of the very institutions that protect our health. The National Institutes of Health, the Centers for Disease Control and Prevention, and yes, the FDA, have all faced budget cuts, staff reductions, and political interference. The American Public Health Association has warned that these rollbacks threaten the health and safety of all Americans. Advertisement At this moment we may want to import something else from Mexico: leadership in public health. There, health advocates and regulators have developed education campaigns and public policy about sugar-sweetened beverages, including those Mexican Cokes, the products of a business model exported from the US, and their links to obesity, type 2 diabetes, and heart disease. They've As a historian, I won't weigh in on whether cane sugar is healthier than corn syrup. That's a question for nutritionists and scientists. But I do know this: a president's personal preferences are no substitute for robust public institutions. You can't regulate a food system by tweet. You can't protect consumers with nostalgia. You can't set policy by piecemeal targeting of products based on particularistic agendas and transactional politics. And you certainly can't build a healthier nation by dismantling the very agencies tasked with safeguarding it. If we're serious about health, we might take a page from Mexico. Because in the end, it's not about which Coke tastes better. It's about which country is doing more to protect its people from the consequences of unchecked sweetness and power.
Medscape
2 hours ago
- Medscape
Me-Too Cancer Drugs Not Often Compared to Original
TOPLINE: In an analysis of all FDA approvals for anticancer drugs from 2009 to 2020, only about 29% of next-in-class drugs were evaluated in head-to-head randomized clinical trials (RCTs) against their first-in-class counterparts. And in these head-to-head RCTs, only 22% of the 'me-too' agents showed a survival benefit compared to the originals. METHODOLOGY: Next-in-class, or 'me-too,' oncology drugs may theoretically offer improved efficacy, safety, or broader indications, yet little is known about how often RCTs directly compare these me-too agents with first-in-class drugs, leaving their true therapeutic value uncertain. Researchers looked at all 332 FDA approvals for anticancer drugs between 2009 and 2020. After excluding supportive care treatments, biosimilars, and drugs with novel routes of administration, 94 RCTs for me-too agents that received FDA approvals were included. The researchers then identified which next-in-class drugs had RCTs comparing them with their first-in-class counterparts, both at and after approval. Among RCTs with head-to-head comparison, primary endpoints varied across trials, with 63% using progression-free survival, 11% using overall survival, and 11% using response rate as their primary endpoint; 77.8% of trials were designed as superiority trials. TAKEAWAY: Only 27 RCTs that led to FDA approvals for me-too drugs — just under 29% — directly compared the new agent to the first-in-class drug (23 regular approvals and four accelerated approvals). Of these 27 RCTs, 12 trials were published at the time of FDA approval and 15 were published after approval. The median time to publication of post-approval trials was 2.8 years for regular approvals and 3.3 years for accelerated approvals. Overall, only six of the 27 trials (22.2%) demonstrated survival benefits, 14 trials (51.9%) met nonsurvival primary endpoints, and six trials (22.2%) failed to meet their primary endpoints. One trial is still ongoing. Among regular approvals designed as superiority trials, only 11 of 17 (64.7%) met their endpoints. Among accelerated approvals designed as superiority trials, three of four achieved their primary endpoints. The remaining six trials were not designed as superiority trials but met their primary endpoints. IN PRACTICE: 'These results suggest a need for regulatory bodies to incentivize within-class RCTs,' the authors wrote, adding that 'in cases where head-to-head RCTs were lacking, it is difficult to assess the true therapeutic value of next-in-class drugs.' SOURCE: This study, led by Timothée Olivier, MD, Geneva University Hospital, Geneva, Switzerland, was published online in JAMA Internal Medicine. LIMITATIONS: Drug development often occurred in parallel, limiting the feasibility of head-to-head comparisons. Some comparative trials published after the analysis period may not have been captured. DISCLOSURES: This project received funding from Arnold Ventures through a grant to the University of California San Francisco. One author reported receiving grants from Arnold Ventures and personal fees from John Hopkins University Press, MedPage, The Free Press, UnitedHealthcare, and other sources, outside the submitted work. Another author disclosed receiving honoraria from MashupMD and Medscape and research funding for his institution from Janssen, outside the submitted work. No other disclosures were reported. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Business Insider
3 hours ago
- Business Insider
Sarepta Stock (SRPT) Rallies on FDA Nod for Broader Gene Therapy Use
Shares of Sarepta Therapeutics (SRPT) jumped over 14% on Tuesday after the FDA authorized the company to restart shipments of its gene therapy for certain Duchenne muscular dystrophy (DMD) patients. SRPT stock has recovered some of its recent losses but remains down over 80% year-to-date. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. FDA Reversal Brings Relief for Sarepta On Monday, the FDA recommended partially lifting the hold on Elevidys shipments. The FDA had used a few rare deaths in patients with advanced DMD as a reason to reconsider the drug's approval and potentially remove it from the market. Now, the agency states that boys who can still walk independently are eligible to receive the gene therapy. This decision aligns with the existing evidence showing the treatment's benefits outweigh the risks. Back in June, the company had paused the use of the therapy in boys who could no longer walk while it investigated the safety concerns. Recently, SRPT stock dropped sharply after the FDA asked Sarepta to stop all Elevidys shipments. The decision came after the therapy was linked to two patient deaths, raising safety concerns. In response, the company voluntarily paused U.S. shipments of the treatment. For context, Elevidys is a one-time gene therapy for DMD in patients aged four and older, and it makes up about half of Sarepta's total revenue. What Is the Price Prediction for SRPT? According to TipRanks, Wall Street has a Hold consensus rating on SRPT stock, based on five Buys, 19 Holds, and five Sells assigned in the last three months. The average Sarepta Therapeutics stock price target of $21.68 implies a 37% upside potential.
